Successful Treatment of Sclerosing Encapsulating Peritonitis with Tamoxifen and Prednisolone.
- Author:
Ji Yoon JUNG
1
;
Won Ik JANG
;
Ji Hyun YOON
;
Eui Sik KIM
;
Sarah CHUNG
;
Dae Eun CHOI
;
Ki Ryang NA
;
Kang Wook LEE
;
Dae Young KANG
;
Young Tai SHIN
Author Information
1. Department of Internal Medicine, College of Medicine Chungnam National University, Daejeon, Korea. kwlee@cnu.ac.kr
- Publication Type:Case Report
- Keywords:
Tamoxifen;
Peritonitis;
Peritoneal dialysis
- MeSH:
Ascites;
Breast Neoplasms;
Humans;
Intestinal Obstruction;
Intestines;
Korea;
Peritoneal Dialysis;
Peritonitis;
Prednisolone;
Tamoxifen;
Ultrafiltration
- From:Korean Journal of Nephrology
2009;28(6):685-692
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sclerosing encapsulating peritonitis (SEP) is an uncommon but serious complication of long-term peritoneal dialysis (PD). Entrapment of the intestine in fibrous tissue, causing complete intestinal obstruction, is referred to as SEP. The usual clinical presentation is with partial or complete small bowel obstruction, ascites, abdominal mass, or impaired peritoneal ultrafiltration. Conservative treatment carries a poor outcome and surgery has offered variable results. Even though there is no established medical treatment, immunosuppressive drugs, steroid and tamoxifen are often used. Tamoxifen is a nonsteroidal anti-estrogenic drug commonly used in the management of breast cancer. To our knowledge, this is the first case of sclerosing encapsulating peritonitis successfully treated with tamoxifen and prednisolone in Korea. Recently, we have treated three SEP patients with tamoxifen and prednisolone. All three patients showed clinical improvement within a few months.
